Jeff Mihalic
Nurix (United States)(US)
Publications by Year
Research Areas
Chronic Lymphocytic Leukemia Research, Protein Degradation and Inhibitors, Cancer-related Molecular Pathways, Epigenetics and DNA Methylation, Regulation of Appetite and Obesity
Most-Cited Works
- → Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development(2014)291 cited
- → Structure-Guided Design, Synthesis, and Evaluation of Guanine-Derived Inhibitors of the eIF4E mRNA–Cap Interaction(2012)220 cited
- → Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton’s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies(2024)87 cited
- → Nx-2127, a Degrader of BTK and IMiD Neosubstrates, for the Treatment of B-Cell Malignancies(2020)46 cited
- → Discovery of potent and specific CXCR3 antagonists(2011)20 cited
- → Discovery and characterization of a potent and selective antagonist of melanin-concentrating hormone receptor 2(2011)18 cited
- → Optimization beyond AMG 232: Discovery and SAR of sulfonamides on a piperidinone scaffold as potent inhibitors of the MDM2-p53 protein–protein interaction(2014)17 cited
- → Thermodynamic Analysis of mRNA Cap Binding by the Human Initiation Factor eIF4E via Free Energy Perturbations(2009)14 cited
- → Targeted Protein Degradation of BTK As a Unique Therapeutic Approach for B Cell Malignancies(2019)2 cited